Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Fig. 2

Effects of minocycline on rash induced by afatinib oral administration (20 mg/kg BW). a Left side is a representative image of control mice with continued administration for 18 days with no treatment. Right side is a representative image of mice pretreated with minocycline WP from 3 days before afatinib administration. b Effects of treatment by WP or minocycline WP after onset of the rash. Left side is treatment with WP, and right side is treatment with minocycline WP from 7 days after the start of administration

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us